Literature DB >> 19878384

Mechanisms of flushing due to niacin and abolition of these effects.

Aditya Sood1, Rohit Arora.   

Abstract

There are many factors that increase the risk of cardiovascular disease, and a prominent factor among these is dyslipidemia. The following literature review focuses on the use of niacin therapy in order to treat dyslipidemia and how to control the associated "niacin flush." The associated studies gathered are reviews and randomized control trials. They were obtained by using electronic searches. Certain keywords took precedence, and articles focusing on niacin therapy were chosen. Recent research has found promising insight into more effective prevention of the niacin-mediated flush through a selective antagonist for the prostaglandin D2 receptor, laropiprant. Aspirin (or NSAIDs) also provide some prevention for flushing, although recent studies have shown that it is not as effective as laropiprant. There is a need for further research in order to come to a clear conclusion regarding combined therapies of aspirin and laropiprant pretreatment, as well as exact dosage requirements. 2009 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19878384      PMCID: PMC8673406          DOI: 10.1111/j.1559-4572.2008.00050.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  38 in total

1.  INITIAL DISTRIBUTION IN MICE OF 3H-LABELED NICOTINIC ACID STUDIED WITH AUTORADIOGRAPHY.

Authors:  L A CARLSON; A HANNGREN
Journal:  Life Sci (1962)       Date:  1964-08

Review 2.  Antiatherogenic small, dense HDL--guardian angel of the arterial wall?

Authors:  Anatol Kontush; M John Chapman
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2006-03

3.  Langerhans cells release prostaglandin D2 in response to nicotinic acid.

Authors:  Dominique Maciejewski-Lenoir; Jeremy G Richman; Yaron Hakak; Ibragim Gaidarov; Dominic P Behan; Daniel T Connolly
Journal:  J Invest Dermatol       Date:  2006-09-28       Impact factor: 8.551

4.  Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells.

Authors:  Zoltán Benyó; Andreas Gille; Clare L Bennett; Björn E Clausen; Stefan Offermanns
Journal:  Mol Pharmacol       Date:  2006-09-28       Impact factor: 4.436

5.  Pharmacokinetics of nicotinic acid-salicylic acid interaction.

Authors:  R W Ding; K Kolbe; B Merz; J de Vries; E Weber; L Z Benet
Journal:  Clin Pharmacol Ther       Date:  1989-12       Impact factor: 6.875

6.  Molecular identification of nicotinic acid receptor.

Authors:  Takatoshi Soga; Masazumi Kamohara; Jun Takasaki; Shun-ichiro Matsumoto; Tetsu Saito; Takahide Ohishi; Hideki Hiyama; Ayako Matsuo; Hitoshi Matsushime; Kiyoshi Furuichi
Journal:  Biochem Biophys Res Commun       Date:  2003-03-28       Impact factor: 3.575

Review 7.  Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia.

Authors:  Paul L McCormack; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

8.  Aspirin blocks nicotinic acid-induced flushing.

Authors:  J K Wilkin; O Wilkin; R Kapp; R Donachie; M E Chernosky; J Buckner
Journal:  Clin Pharmacol Ther       Date:  1982-04       Impact factor: 6.875

Review 9.  The nicotinic acid receptor--a new mechanism for an old drug.

Authors:  Fredrik Karpe; Keith N Frayn
Journal:  Lancet       Date:  2004-06-05       Impact factor: 79.321

10.  Peroxisome proliferator-activated receptor-alpha activation inhibits Langerhans cell function.

Authors:  Sandrine Dubrac; Patrizia Stoitzner; Daniela Pirkebner; Andreas Elentner; Kristina Schoonjans; Johan Auwerx; Sem Saeland; Paul Hengster; Peter Fritsch; Nikolaus Romani; Matthias Schmuth
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

View more
  4 in total

1.  Similar maximum systemic but not local cyclooxygenase-2 inhibition by 50 mg lumiracoxib and 90 mg etoricoxib: a randomized controlled trial in healthy subjects.

Authors:  Lisa Felden; Carmen Walter; Carlo Angioni; Yannick Schreiber; Nils von Hentig; Nerea Ferreiros; Gerd Geisslinger; Jörn Lötsch
Journal:  Pharm Res       Date:  2014-01-28       Impact factor: 4.200

2.  High density lipoproteins-based therapies for cardiovascular disease.

Authors:  Xuan Gao; Shujun Yuan
Journal:  J Cardiovasc Dis Res       Date:  2010-07

3.  Extended release niacin-laropiprant in patients with hypercholesterolemia or mixed dyslipidemias improves clinical parameters.

Authors:  Helen Vosper
Journal:  Clin Med Insights Cardiol       Date:  2011-09-19

Review 4.  Metabolic pancreatitis: Etiopathogenesis and management.

Authors:  Sunil Kumar Kota; S V S Krishna; Sandeep Lakhtakia; Kirtikumar D Modi
Journal:  Indian J Endocrinol Metab       Date:  2013-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.